A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Acerta Pharma BV
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Michigan Rogel Cancer Center
AstraZeneca
AstraZeneca
AstraZeneca
Dana-Farber Cancer Institute
Institute of Cancer Research, United Kingdom
M.D. Anderson Cancer Center
AstraZeneca
Massachusetts General Hospital
AstraZeneca
University of Birmingham
Assistance Publique Hopitaux De Marseille
Seoul National University Hospital